Radiotherapy and targeted therapy are essential treatments for patients with brain metastases from human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, the combination of radiotherapy and targeted therapy still needs to be investigated, and neurotoxicity induced by radiotherapy for brain metastases has also become an important issue of clinical concern. It remained unclear how to achieve the balance of efficacy and toxicity with the application of new radiotherapy techniques and new targeted therapy drugs. This article reviews the benefits and potential risk of combining radiotherapy and targeted therapy for HER2-positive breast cancer with brain metastases.

<p>Summary of Exposure to ZKAB001, All Treated Patient Population</p>

<p>Representativeness of study participants</p>

<p>ZKAB001 related TRAE That Occurred in all treated Patient Population</p>

<p>Representativeness of study participants</p>

<p>Kaplan-Meier curves for Event-free Survival (EFS) in each dose group</p>

<p>ZKAB001 related TRAE That Occurred in all treated Patient Population</p>

<p>Pharmacokinetic parameters after multiple administration</p>